ArticleScientific reports2026
The role of cellular senescence-related genes in ischemia-reperfusion injury and the identification of their biomarkers.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cellular senescence-related genes significantly influence the pathophysiology of ischemia–reperfusion injury (IRI). And identifying their shared biomarkers may improve the diagnosis and treatment of IRI. We analyzed three datasets (GSE61592, GSE67308, GSE83472) from the Gene Expression Omnibus database, and intersected them with the cellular senescence-related dataset to obtain 26 significantly altered cellular senescence-related differentially expressed genes in IRI. We used machine learning methods, including logistic regression, LASSO regression for feature screening, and SVM analysis, to construct a model identifying 6 key genes (CDKN2B, TP53, ZNF277, ID1, STAT3, TERF2). Internal validation shows that the model has high diagnostic accuracy. Immune infiltration analysis revealed a significant increase in 20 immune cell subpopulations in IRI. Among these, CDKN2B showed a strong correlation with central memory CD4 + T cells. Furthermore, regulatory network analysis revealed that TP53 is a high-priority drug target; TERF2 is a hub gene regulated by transcription factors; and ID1 and STAT3 are hub genes regulated by miRNAs. Finally, we validated the differential expression of these 6 genes in a mouse IRI model by qRT-PCR and immunohistochemistry. Overall, this study established a novel diagnostic model containing 6 genes. This model provides new insights into the pathological mechanisms of IRI and offers new directions for improving the early diagnosis and targeted treatment of IRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.